Practice guideline update summary: Pharmacologic treatment for pediatric migraine prevention: Report of the Guideline Development, Dissemination, and Implementation Subcommittee of the American Academy of Neurology and the American Headache Society.
Academies and Institutes
/ standards
Adolescent
Analgesics
/ administration & dosage
Anticonvulsants
/ administration & dosage
Child
Decision Making, Shared
Headache
/ drug therapy
Humans
Migraine Disorders
/ drug therapy
Neurology
/ standards
Practice Guidelines as Topic
/ standards
Research Report
/ standards
Societies, Medical
/ standards
Treatment Outcome
United States
/ epidemiology
Journal
Neurology
ISSN: 1526-632X
Titre abrégé: Neurology
Pays: United States
ID NLM: 0401060
Informations de publication
Date de publication:
10 09 2019
10 09 2019
Historique:
received:
21
12
2018
accepted:
14
05
2019
pubmed:
16
8
2019
medline:
31
1
2020
entrez:
16
8
2019
Statut:
ppublish
Résumé
To provide updated evidence-based recommendations for migraine prevention using pharmacologic treatment with or without cognitive behavioral therapy in the pediatric population. The authors systematically reviewed literature from January 2003 to August 2017 and developed practice recommendations using the American Academy of Neurology 2011 process, as amended. Fifteen Class I-III studies on migraine prevention in children and adolescents met inclusion criteria. There is insufficient evidence to determine if children and adolescents receiving divalproex, onabotulinumtoxinA, amitriptyline, nimodipine, or flunarizine are more or less likely than those receiving placebo to have a reduction in headache frequency. Children with migraine receiving propranolol are possibly more likely than those receiving placebo to have an at least 50% reduction in headache frequency. Children and adolescents receiving topiramate and cinnarizine are probably more likely than those receiving placebo to have a decrease in headache frequency. Children with migraine receiving amitriptyline plus cognitive behavioral therapy are more likely than those receiving amitriptyline plus headache education to have a reduction in headache frequency. The majority of randomized controlled trials studying the efficacy of preventive medications for pediatric migraine fail to demonstrate superiority to placebo. Recommendations for the prevention of migraine in children include counseling on lifestyle and behavioral factors that influence headache frequency and assessment and management of comorbid disorders associated with headache persistence. Clinicians should engage in shared decision-making with patients and caregivers regarding the use of preventive treatments for migraine, including discussion of the limitations in the evidence to support pharmacologic treatments.
Identifiants
pubmed: 31413170
pii: WNL.0000000000008105
doi: 10.1212/WNL.0000000000008105
pmc: PMC6746206
doi:
Substances chimiques
Analgesics
0
Anticonvulsants
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
500-509Commentaires et corrections
Type : ErratumIn
Type : CommentIn
Informations de copyright
© 2019 American Academy of Neurology.
Références
Cephalalgia. 2018 Jan;38(1):1-211
pubmed: 29368949
Dev Med Child Neurol. 1984 Dec;26(6):737-41
pubmed: 6519358
Eur Neurol. 1986;25(1):32-5
pubmed: 3510125
N Engl J Med. 2017 Jan 12;376(2):115-124
pubmed: 27788026
Pediatrics. 1987 Apr;79(4):593-7
pubmed: 3822681
Headache. 2005 Nov-Dec;45(10):1304-12
pubmed: 16324162
J Pediatr. 2014 Oct;165(4):659-65
pubmed: 25063720
Headache. 2009 Feb;49(2):170-7
pubmed: 18783447
Arch Neurol. 2011 Oct;68(10):1275-81
pubmed: 21670385
Pediatrics. 2009 Mar;123(3):924-34
pubmed: 19255022
Headache. 2018 May;58(5):661-675
pubmed: 29516477
Neurology. 1999 Apr 22;52(7):1507-10
pubmed: 10227648
Pain Rep. 2017 Jul 26;2(4):e612
pubmed: 29392227
J Pain. 2016 Aug;17(8):855-873.e8
pubmed: 27102894
Neurology. 2008 Jul 22;71(4):272-6
pubmed: 18645165
Cephalalgia. 1988 Mar;8(1):1-6
pubmed: 3282670
Headache. 1990 Apr;30(5):264-8
pubmed: 2191938
Headache. 2008 Jul;48(7):1012-25
pubmed: 18705027
Headache. 2015 Nov-Dec;55(10):1382-96
pubmed: 26198185
Neurology. 2002 Jun 11;58(11):1652-9
pubmed: 12058094
Neurology. 2009 Jul 14;73(2):142-9
pubmed: 19398680
Neurology. 2016 Nov 1;87(18):1943-1953
pubmed: 27581218
Headache. 2017 Mar;57(3):349-362
pubmed: 28028812
Neurology. 2015 Sep 8;85(10):866-72
pubmed: 26085607
Pediatr Neurol. 2014 Oct;51(4):503-8
pubmed: 25023977
J Child Neurol. 2007 Jul;22(7):829-35
pubmed: 17715274
Cephalalgia. 2010 Sep;30(9):1065-72
pubmed: 20713557
Acta Paediatr. 2017 Dec;106(12):1961-1965
pubmed: 28708256
Cochrane Database Syst Rev. 2014 May 05;(5):CD003968
pubmed: 24796681
Acta Neurol Scand. 1974;50(1):109-15
pubmed: 4839065
Cephalalgia. 2009 Apr;29(4):436-44
pubmed: 19170687
Neurology. 2001 Dec 11;57(11):2034-9
pubmed: 11739822
Dev Med Child Neurol. 1982 Dec;24(6):837-41
pubmed: 6218003
Headache. 2010 Jun;50(6):921-36
pubmed: 20487038
Headache. 1977 Mar;17(1):28-31
pubmed: 321395
Cephalalgia. 2013 Jul;33(9):629-808
pubmed: 23771276
Cephalalgia. 2004;24 Suppl 1:9-160
pubmed: 14979299
Neurology. 2010 Aug 24;75(8):712-7
pubmed: 20720191
Epilepsia. 2016 Jul;57(7):1048-52
pubmed: 27265509
Headache. 2010 Feb;50(2):210-8
pubmed: 19804389
Epilepsia. 2003 Apr;44(4):540-9
pubmed: 12681003
JAMA. 2013 Dec 25;310(24):2622-30
pubmed: 24368463
Neurology. 2004 Mar 9;62(5):788-90
pubmed: 15007133
JAMA. 2013 Apr 24;309(16):1696-703
pubmed: 23613074